Boston Scientific Corporation
BSX
$51.08
$0.621.22%
NYSE
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 13.53% | 17.44% | 19.88% | 21.62% | 21.45% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 13.53% | 17.44% | 19.88% | 21.62% | 21.45% |
| Cost of Revenue | 7.56% | 15.60% | 18.47% | 23.23% | 23.95% |
| Gross Profit | 16.33% | 18.29% | 20.53% | 20.89% | 20.31% |
| SG&A Expenses | 10.36% | 13.75% | 15.11% | 15.91% | 19.44% |
| Depreciation & Amortization | 5.03% | 5.57% | 4.67% | 6.43% | 3.68% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.80% | 15.37% | 17.15% | 19.47% | 20.75% |
| Operating Income | 30.14% | 26.57% | 32.37% | 31.59% | 24.65% |
| Income Before Tax | 28.74% | 51.01% | 48.29% | 48.34% | 39.88% |
| Income Tax Expenses | -61.75% | -59.69% | 12.84% | 17.15% | 57.37% |
| Earnings from Continuing Operations | 46.94% | 75.84% | 56.66% | 55.56% | 36.82% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -25.00% | -25.00% | -14.29% | 100.00% | 100.00% |
| Net Income | 46.71% | 75.44% | 56.40% | 55.66% | 36.96% |
| EBIT | 30.14% | 26.57% | 32.37% | 31.59% | 24.65% |
| EBITDA | 23.79% | 21.31% | 25.06% | 24.87% | 19.18% |
| EPS Basic | 46.33% | 74.43% | 55.46% | 54.66% | 36.08% |
| Normalized Basic EPS | 31.79% | 26.54% | 30.19% | 30.19% | 25.36% |
| EPS Diluted | 47.16% | 74.65% | 55.39% | 54.79% | 36.54% |
| Normalized Diluted EPS | 32.23% | 26.77% | 30.22% | 30.06% | 25.14% |
| Average Basic Shares Outstanding | 0.26% | 0.59% | 0.60% | 0.61% | 0.60% |
| Average Diluted Shares Outstanding | -0.05% | 0.42% | 0.58% | 0.71% | 0.78% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |